Menu Back toSession-2-Track-1-Business-Impacts-to-IDMP
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Regulatory Submissions, Information, and Document Management Forum
Session 2 Track 1: Business Impacts to IDMP
Vada A. Perkins, DrSc, MSc
- Executive Director, Regulatory Policy and Intelligence
- Bayer Pharmaceuticals, United States
Explore some of the opportunities and challenges of addressing IDMP integration within the pharmaceutical environment. Discussion topics include collaborative processes and principles for successful assessment and implementation of an IDMP program, along with a case-study from a company perspective to provide lessons learned in their approach to IDMP to deliver business improvements.
Learning Objective : Ability to identify and ultimately plan for a synergistic IDMP/RIM program. Plan for and perform analysis on various processes in order to formulate an action plan for long term compliance. Describe and share with colleagues the long term goal of IDMP, how it's not just about data, as well has how other agency activities come into play.
Collaborative Processes for a Successful IDMP Program
- IRISS Forum, United States
IDMP Readiness – Status Based on Pharmaceutical Company Assessments in Europe
Thomas Hornbaek Svendsen, MS
- Managing Consultant
- NNIT A/S, Denmark
Sponsor Perspective Case Study
Christian A. Buckley, MBA, RAC
- Associate Director, Regulatory Affairs
- Astellas, United States